Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 3/2012

01-03-2012 | Original Article

Falls in persons with chemotherapy-induced peripheral neuropathy

Authors: Cindy Tofthagen, Janine Overcash, Kevin Kip

Published in: Supportive Care in Cancer | Issue 3/2012

Login to get access

Abstract

Purpose

The purpose of this study was to evaluate possible risk factors for falls in a group of patients with chemotherapy-induced peripheral neuropathy (CIPN).

Methods

This prospective, descriptive study included persons receiving paclitaxel, docetaxel, oxaliplatin, or cispatin who reported at least one symptom of CIPN. Each patient was invited to complete the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool (CIPNAT) and a demographic data questionnaire. Data were analyzed using descriptive statistics and logistic regression.

Results

In this sample (n = 109), fallers (n = 21) had higher doses of chemotherapy(p = 0.045), more neuropathic symptoms (p = 0.016), higher scores on the symptom experience (p = 0.005) and interference items (=0.001) on the CIPNAT, more severe muscle weakness (p < 0.001) and loss of balance (p < 0.001), and higher interference with walking(p < 0.001) and driving (p = 0.022). Patients who received taxanes were more likely to have fallen than patients who received platinum-based chemotherapy (p = 0.022). No significant differences in age or disease stage between fallers and non-fallers were present. Severity of loss of balance and cycle number was independently associated with falling.

Conclusions

This study demonstrates that the risk of falls increases with each cycle of chemotherapy and that patients receiving taxanes may be at greater risk of falls than patients receiving neurotoxic platinum-based drugs. Patients who report muscle weakness and loss of balance or say that their symptoms interfere with walking or driving may be at a higher risk of falls.
Literature
1.
2.
Overcash J (2007) Prediction of falls in older adults with cancer: a preliminary study. Oncol Nurs Forum 34(2):341–346PubMedCrossRef
3.
Holley S (2002) A look at the problem of falls among people with cancer. Clin J Oncol Nurs 6(4):193–197PubMedCrossRef
4.
Joseph EK, Levine JD (2009) Comparison of oxaliplatin- and cisplatin-induced painful peripheral neuropathy in the rat. J Pain 10(5):534–541PubMedCrossRef
5.
Lee JJ, Swain SM (2006) Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 24(10):1633–1642PubMedCrossRef
6.
Lipton RB, Apfel SC, Dutcher JP, Rosenberg R, Kaplan J, Berger A, Einzig AI, Wiernik P, Schaumburg HH (1989) Taxol produces a predominantly sensory neuropathy. Neurology 39(3):368–373PubMed
7.
Flatters SJ, Bennett GJ (2006) Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain 122(3):245–257PubMedCrossRef
8.
Joseph EK, Chen X, Bogen O, Levine JD (2008) Oxaliplatin acts on IB4-positive nociceptors to induce an oxidative stress-dependent acute painful peripheral neuropathy. J Pain 9(5):463–472PubMedCrossRef
9.
Bove L, Picardo M, Maresca V, Jandolo B, Pace A (2001) A pilot study on the relation between cisplatin neuropathy and vitamin E. J Exp Clin Canc Res 20(2):277–280
10.
Kruse RL, Lemaster JW, Madsen RW (2010) Fall and balance outcomes after an intervention to promote leg strength, balance, and walking in people with diabetic peripheral neuropathy: “feet first” randomized controlled trial. Phys Ther 90:1568–1579PubMedCrossRef
11.
Son J, Ashton-Miller JA, Richardson JK (2009) Frontal plane ankle proprioceptive thresholds and unipedal balance. Muscle Nerve 39(2):150–157PubMedCrossRef
12.
Richardson JK, Ashton-Miller JA (1996) Peripheral neuropathy: an often-overlooked cause of falls in the elderly. Postgrad Med 99(6):161–172PubMed
13.
Tilling LM, Darawil K, Britton M (2006) Falls as a complication of diabetes mellitus in older people. J Diab Complications 20(3):158–162CrossRef
14.
Herndon JG, Helmick CG, Sattin RW, Stevens JA, DeVito C, Wingo PA (1997) Chronic medical conditions and risk of fall injury events at home in older adults. J Am Geriatr Soc 45(6):739–743PubMed
15.
Pandya N, Bookhart B, Mody SH, Funk Orsini PA, Reardon G (2008) Study of anemia in long-term care (SALT): prevalence of anemia and its relationship with the risk of falls in nursing home residents. Curr Med Res Opin 24(8):2139–2149PubMedCrossRef
16.
Donald IP, Bulpitt CJ (1999) The prognosis of falls in elderly people living at home. Age Ageing 28(2):121–125PubMedCrossRef
17.
Helbostad JL, Leirfall S, Moe-Nilssen R, Sletvold O (2007) Physical fatigue affects gait characteristics in older persons. J Gerontol A Biol Sci Med Sci 62(9):1010–1015PubMedCrossRef
18.
19.
Katz S, Downs TD, Cash HR, Grotz RC (1970) Progress in development of the index of ADL. Gerontologist 10(1):20–30PubMedCrossRef
20.
Feldblum I, German L, Bilenko N, Shahar A, Enten R, Greenberg D, Harman I, Castel H, Shahar DR (2009) Nutritional risk and health care use before and after an acute hospitalization among the elderly. Nutrition 25:415–420PubMedCrossRef
21.
Carey EC, Covinsky KE, Lui LY, Eng C, Sands LP, Walter LC (2008) Prediction of mortality in community-living frail elderly people with long-term care needs. J Am Geriatr Soc 56(1):68–75PubMedCrossRef
22.
Balducci L (2007) Aging, frailty, and chemotherapy. Cancer Control 14(1):7–12PubMed
23.
Podsiadlo D, Richardson S (1991) The timed “Up & Go”: a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 39(2):142–148PubMed
24.
Gale CR, Martyn CN, Cooper C, Sayer AA (2007) Grip strength, body composition, and mortality. Int J Epidemiol 36(1):228–235PubMedCrossRef
25.
Wrobel JS, Crews RT, Connolly JE (2009) Clinical factors associated with a conservative gait pattern in older male veterans with diabetes. J Foot Ankle Res 2:11PubMedCrossRef
26.
Paul L, Ellis BM, Leese GP, McFadyen AK, McMurray B (2009) The effect of a cognitive or motor task on gait parameters of diabetic patients, with and without neuropathy. Diabet Med 26(3):234–239PubMedCrossRef
27.
Macgilchrist C, Paul L, Ellis BM, Howe TE, Kennon B, Godwin J (2010) Lower-limb risk factors for falls in people with diabetes mellitus. Diabet Med 27(2):162–168PubMedCrossRef
28.
Hile ES, Fitzgerald GK, Studenski SA (2010) Persistent mobility disability after neurotoxic chemotherapy. Phys Ther 90:1649–1657PubMedCrossRef
29.
Richardson JK, Sandman D, Vela S (2001) A focused exercise regimen improves clinical measures of balance in patients with peripheral neuropathy. Arch Phys Med Rehabil 82(2):205–209PubMedCrossRef
30.
Balducci S, Iacobellis G, Parisi L, Di Biase N, Calandriello E, Leonetti F, Fallucca F (2006) Exercise training can modify the natural history of diabetic peripheral neuropathy. J Diab Complications 20(4):216–223CrossRef
31.
Ruhland JL, Shields RK (1997) The effects of a home exercise program on impairment and health-related quality of life in persons with chronic peripheral neuropathies. Phys Ther 77(10):1026–1039PubMed
32.
Bulat T, Hart-Hughes S, Ahmed S, Quigley P, Palacios P, Werner DC, Foulis P (2007) Effect of a group-based exercise program on balance in elderly. Clin Interv Aging 2(4):655–660PubMed
33.
de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16):2938–2947PubMed
34.
Hilpert F, Stahle A, Tome O, Burges A, Rossner D, Spathe K, Heilmann V, Richter B, du Bois A (2005) Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy—a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group. Support Care Cancer 13(10):797–805PubMedCrossRef
35.
Hochster HS, Grothey A, Childs BH (2007) Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol 25(25):4028–4029PubMedCrossRef
36.
Bakitas MA (2007) Background noise: the experience of chemotherapy-induced peripheral neuropathy. Nurs Res 56(5):323–331PubMedCrossRef
37.
Tofthagen C (2010) Patient perceptions associated with chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs 14(3):E22–E28PubMedCrossRef
38.
Visovsky C, Collins M, Abbott L, Aschenbrenner J, Hart C (2007) Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs 11(6):901–913PubMedCrossRef
39.
Wampler MA, Hamolsky D, Hamel K, Melisko M, Topp KS (2005) Case report: painful peripheral neuropathy following treatment with docetaxel for breast cancer. Clin J Oncol Nurs 9(2):189–193PubMedCrossRef
40.
Tofthagen C, McMillan SC, Kip K (2011) Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool. Cancer Nurs (in press)
41.
Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK (2004) Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 29(3):387–392PubMedCrossRef
42.
Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG (2007) Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 110:1042–1049PubMedCrossRef
43.
Storey DJ, Sakala M, McLean CM, Phillips HA, Dawson LK, Wall LR, Fallon MT, Clive S (2010) Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy? Ann Oncol 21:1657–1661PubMedCrossRef
44.
Argyriou AA, Polychronopoulos P, Koutras A, Iconomou G, Gourzis P, Assimakopoulos K, Kalofonos HP, Chroni E (2006) Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy? Support Care Cancer 14(3):223–229PubMedCrossRef
45.
Dunlap B, Paice JA (2006) Chemotherapy-induced peripheral neuropathy: a need for standardization in measurement. J Support Oncol 4(8):398–399PubMed
Metadata
Title
Falls in persons with chemotherapy-induced peripheral neuropathy
Authors
Cindy Tofthagen
Janine Overcash
Kevin Kip
Publication date
01-03-2012
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 3/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-011-1127-7

Other articles of this Issue 3/2012

Supportive Care in Cancer 3/2012 Go to the issue

Original Article

Recommending early integration of palliative care — does it work?

Original Article

Symptoms of the oral cavity and their association with local microbiological and clinical findings—a prospective survey in palliative care

Original Article

Relationships between the characteristics of oncohematology services providing palliative care and the sociodemographic characteristics of caregivers using health indicators: social support, perceived stress, coping strategies, and quality of work life

Original Article

Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study

Short Communication

Aprepitant, dexamethasone, and palonosetron in the prevention of doxorubicin/cyclophosphamide-induced nausea and vomiting

Original Article

Differential responses of fibroblasts, non-neoplastic epithelial cells, and oral carcinoma cells to low-level laser therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits